Doxazosin and Single-Drug Therapy in Hypertensive Patients
Doxazosin and Single-Drug Therapy in Hypertensive Patients
Source: Martell N, Luque M. J Clin Hypertens. 2001;3:218-223.
In middle age and beyond, both hypertension and benign prostatic hyperplasia (BPH) become increasingly common. Treatment of normotensive BPH patients can usually be accomplished using alpha-blockers without problematic episodes of hypotension. For hypertensive BPH patients, there has been some concern that addition of doxazosin to the antihypertensive regimen might produce hypotension or other untoward effects. This study evaluated the effect of 2-4 mg QD doxazosin added to the regimen of patients who had a achieved a diastolic blood pressure < 95 on nonalpha blocker monotherapy.
Patients (n = 2363, Spanish men > age 40) were followed for 14 weeks, and evaluated by a quality-of-life scale, prostatism symptom scale, blood pressure measurement, and recording of adverse events.
Doxazosin treatment resulted in a mean blood pressure reduction of 10.7/6.1 over baseline treatment with
an ACE inhibitor, calcium channel blocker, or diuretic. Favorable effects for prostatism scores were consistently seen. Symptoms of dizziness, vertigo, hypotension, or syncope were seen uncommonly (2.7%, 0.4%, 0.8%, 0.3%, respectively). Martell and Luque conclude that addition of an alpha-blocker to the treatment regimen of hypertensive BPH patients is generally effective and well tolerated.
The Therapeutics & Drug Briefs were written by Louis Kuritzky, MD.
Attention Readers
In the August 2001, issue on page 5 in the article, "Pioglitazone Improves Lipid Profiles More Effectively than Rosiglitazone," the sentence in the second paragraph, "Mean cholesterol, triglyceride, and low-density lipoprotein (LDL) cholesterol levels decreased in the pioglitazone group by 44.7%, 11.3%, and 7.3% but increased 8.4%, 38.4%, and 8.1%, respectively, in the rosiglitazone group," should have read ". . .cholesterol levels decreased in the pioglitazone group by 4.7%." We regret any confusion this may have caused.
Readers are Invited. . .
Readers are invited to submit questions or comments on material seen in or relevant to Physician’s Therapeutics & Drug Alert. Send your questions to: Robert Kimball, Physician’s Therapeutics & Drug Alert, c/o American Health Consultants, P.O. Box 740059, Atlanta, GA 30374. For subscription information, you can reach the editors and customer service personnel for Physician’s Therapeutics & Drug Alert via the internet by sending e-mail to: [email protected].
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.